Ctrl Worx Watch List › Company

BioRestorative Therapies, Inc. (BRTX): material weakness open at least 2,494 days

By Russell Tomoum, Ctrl Worx™. Built from its own SEC filings. How the Clock works.

BioRestorative Therapies, Inc. reported ineffective internal control over financial reporting because of a material weakness in 20 filings since Mar 18, 2021. It stated one or more material weaknesses in 7 more SEC filings that gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Mar 31, 2026.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #10866

Causes the company named

Entity-level and governance · 27Financial close and reporting · 22Accounting expertise and resources · 14Complex or non-routine accounting · 8Segregation of duties · 8Tax · 2

Lack of formal policies, risk assessment procedures, and effective controls over journal entries, reconciliations, and tax accounting.

What the latest filing says

As a result of the material weaknesses in internal controls over financial reporting described below, we concluded that our disclosure controls and procedures as of March 31, 2026 were not effective. 25 Material Weaknesses in Internal Control over Financial Reporting A material weakness, as defined in the standards established by Sarbanes-Oxley, is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP. The following material weaknesses in our internal control over financial reporting were present as of December 31, 2025 and continued to exist as of March 31, 2026: ● Lack of adherence to formal policies and procedures; ● Lack of risk assessmen [...]

From the controls section of the 10-Q filed May 14, 2026. Read the full filing on SEC EDGAR.

Company response: BioRestorative Therapies, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

Follow BRTX for free

Get an email when BioRestorative Therapies, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with BioRestorative Therapies, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.